Obiltoxaximab

Obiltoxaximab (brand name Obiltoxaximab-abrila) is a monoclonal antibody used to treat certain types of inhalation anthrax. It is a recombinant IgG1 kappa monoclonal antibody that binds to the anthrax toxin protective antigen (PA) and prevents it from forming a complex with other toxins. It is administered via intravenous infusion and is indicated for use in adults and children aged 2 years and older. Obiltoxaximab is the only approved anthrax treatment for inhalational anthrax in the US.

Obiltoxaximab, also known by brand names like Anthim and Nyxthracis, functions as a monoclonal antibody medication specifically designed to combat the effects of Bacillus anthracis, the bacterium responsible for anthrax.

Here's a closer look at its key aspects:

Purpose:

  • Combats anthrax exposure: Obiltoxaximab targets the toxin produced by Bacillus anthracis. This toxin is the primary cause of severe illness and death in anthrax infections.
  • Neutralizes toxin: Obiltoxaximab binds to a specific component of the anthrax toxin, preventing it from entering the body's cells. By doing so, it effectively neutralizes the toxin's harmful effects.

Applications:

  • Treatment: Obiltoxaximab is primarily used in combination with appropriate antibiotics to treat inhalational anthrax, a severe form of the infection contracted through breathing in anthrax spores.
  • Prophylaxis: In situations where alternative therapies are unavailable or unsuitable, Obiltoxaximab can also be used as post-exposure prophylaxis to prevent the onset of inhalational anthrax in individuals who have potentially been exposed to the spores.

Important to Remember:

  • Prescription medication: Obiltoxaximab is a prescription-only drug and should only be administered under the guidance of a qualified healthcare professional in a healthcare setting.
  • Not a substitute for antibiotics: While crucial in neutralizing the toxin, Obiltoxaximab does not eliminate the bacteria itself. Therefore, it's always used in conjunction with appropriate antibiotics to combat the bacterial infection.
  • Potential side effects: As with any medication, Obiltoxaximab can cause side effects, including fever, chills, headache, and nausea. In rare cases, more serious reactions may occur.
Anatomical Therapeutic Chemical Classification
J - Antiinfectives for systemic use
J06 Immune sera and immunoglobulins
J06B - Immunoglobulins
J06BC Antibacterial monoclonal antibodies
External Links